Kalpa Tesamorelin 5 mg GHRH Analogue Research Vial for Labs

It is a lyophilised research vial containing 5 mg of tesamorelin, a GHRH analogue. The peptide binds the growth hormone releasing hormone receptor and produces a transient rise in endogenous growth hormone and IGF-1, and its licensed forms are marketed as Egrifta and Egrifta SV for a specific clinical indication. This vial is a research material without a licensed label of its own.

It activates the GHRH receptor on pituitary cells and triggers a pulse of growth hormone release, which lifts IGF-1 for a limited time. Because the peptide works through the body's own release mechanism, the effect depends on pituitary function rather than on delivered hormone. That is the same principle behind sermorelin, although the two peptides clear at very different rates.

General references give an elimination half-life of 26 to 38 minutes, while the FDA label for the SV form lists about 8 minutes. The two figures reflect different formulations of the licensed product, so neither describes this research vial directly. The practical point is that the peptide acts for less than an hour, which keeps the growth hormone pulse short.

Two and a half millilitres of bacteriostatic water give 2 mg per ml, so the 2 mg clinical amount measures 1 ml on a U-100 syringe; 5 ml gives 1 mg per ml and the same amount measures 2 ml. Add the solvent down the vial wall and do not shake it, then store the solution at 2-8 C without freezing and follow the use window on the vial.

The licensed injections commonly cause injection site reactions, and a 2026 review of unregulated GH peptides adds fluid retention, oedema and joint discomfort across the class. Those class findings are not specific to tesamorelin. Because the research vial has no approved label, formal adverse event data do not exist for it, and long term effects remain unknown.

Yes. Tesamorelin is named directly in class S2 of the WADA prohibited list, the class for growth hormone releasing factors and secretagogues, and it is prohibited at all times. That is a stricter position than the incretin peptides such as semaglutide, which appear only in the monitoring programme, so there is no permitted use for a tested athlete.

Yes. The 5 mg vial is listed on this page with international and U.S. domestic shipping options, and the price charged matches the option you select. Orders are dispatched after payment confirmation. The product is sold strictly for laboratory research and is not a licensed medicine, so the prescription versions remain a doctor's decision.